17 completed, 1 terminated. 18 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Completed 17, Terminated 1 |
Follow Erosive Esophagitis: new trials by email Literature Review of Erosive Esophagitis trials Research Report on Erosive Esophagitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease BLI5100 - Non-erosive Reflux Disease, Erosive Esophagitis | Phase 3 | Completed | Braintree Laboratories | 400 | 2023-04-05 | 2025-09-26 |
| A Study to Evaluate the Efficacy and Safety of BLI5100 in Patients With Erosive Esophagitis BLI5100, PPI Control - Erosive Esophagitis | Phase 3 | Completed | Braintree Laboratories | 1250 | 2022-10-30 | 2026-06-16 |
| Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis. Nexium 20mg, Nexium 10mg - Erosive Esophagitis | Phase 3 | Completed | AstraZeneca | 53 | 2022-07-01 | 2026-10-13 |
| JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis JP-1366 20mg, Esomeprazole 40mg - Erosive Esophagitis | Phase 3 | Completed | Onconic Therapeutics Inc. | 300 | 2022-01-17 | 2024-08-27 |
| Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis Vonoprazan, Lansoprazole - Erosive Esophagitis | Phase 3 | Completed | Phathom Pharmaceuticals, Inc. | 1027 | 2019-10-28 | 2022-07-29 |
| Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD) YYD601 40mg, Nexium 40mg, Placebos - Erosive Esophagitis | Phase 3 | Completed | Yooyoung Pharmaceutical Co., Ltd. | 170 | 2019-01-29 | 2021-05-11 |
| Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3) DWP14012 40mg, DWP14012 40mg placebo, Esomeprazole 40mg - Erosive Esophagitis | Phase 3 | Completed | Daewoong Pharmaceutical Co. LTD. | 263 | 2018-12-13 | 2020-09-03 |
| Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis Dexlansoprazole, Lansoprazole, Placebo - Erosive Esophagitis | Phase 3 | Terminated | Takeda | 37 | 2016-12-21 | 2019-02-22 |
| Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis CJ-12420 100mg QD, Esomeprazole 40mg, CJ-12420 50mg QD - Erosive Esophagitis | Phase 3 | Completed | HK inno.N Corporation | 302 | 2016-05-02 | 2017-09-12 |
| Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis CJ-12420 100 mg QD, Esomeprazole 40 mg QD - Erosive Esophagitis | Phase 3 | Completed | HK inno.N Corporation | 280 | 2015-05-01 | 2016-12-15 |
| Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis Vonoprazan, Lansoprazole, Vonoprazan Placebo - Erosive Esophagitis | Phase 3 | Completed | Takeda | 703 | 2015-04-01 | 2020-02-21 |
| Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis Vonoprazan, Lansoprazole, Vonoprazan Placebo - Erosive Esophagitis | Phase 3 | Completed | Takeda | 481 | 2015-03-24 | 2019-06-03 |
| A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis TAK-438 - Erosive Esophagitis | Phase 3 | Completed | Takeda | 19 | 2012-07-01 | 2014-02-10 |
| A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients Lafutidine, Famotidine, Omeprazole - Erosive Esophagitis | Phase 3 | Completed | Boryung Pharmaceutical Co., Ltd | 495 | 2011-11-01 | 2025-01-15 |
| Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Maintenance Treatment of Healed Erosive Esophagitis TAK-438, Lansoprazole - Erosive Esophagitis | Phase 3 | Completed | Takeda | 607 | 2011-10-01 | 2013-08-23 |
| Long-Term Safety Study of TAK-438 in the Maintenance Treatment of Healed Erosive Esophagitis TAK-438 - Erosive Esophagitis | Phase 3 | Completed | Takeda | 305 | 2011-09-01 | 2013-11-05 |
| Efficacy Study of Ilaprazole to Treat Erosive Esophgitis Ilaprazole, Lansoprazole - Erosive Esophagitis, GERD | Phase 3 | Completed | Il-Yang Pharm. Co., Ltd. | 292 | 2010-07-01 | 2012-01-12 |
| Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Erosive Esophagitis TAK-438, Placebo, Lansoprazole - Erosive Esophagitis | Phase 3 | Completed | Takeda | 409 | 2012-11-09 |
Gastroesophageal Reflux (2) · Non-Erosive Reflux Disease (1)
Deglutition Disorders (3) · Digestive System Diseases (3) · Esophageal Diseases (3) · Esophageal Motility Disorders (3) · Gastrointestinal Diseases (3) · Gastroesophageal Reflux (1)
1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine (7) · Lansoprazole (7) · Esomeprazole (6) · Dexlansoprazole (1) · Famotidine (1) · Omeprazole (1) · fexuprazan (1) · ilaprazole (1) · lafutidine (1) · tegoprazan (1)
Takeda (7) · Braintree Laboratories (2) · HK inno.N Corporation (2) · AstraZeneca (1) · Boryung Pharmaceutical Co., Ltd (1) · Daewoong Pharmaceutical Co. LTD. (1) · Il-Yang Pharm. Co., Ltd. (1) · Onconic Therapeutics Inc. (1) · Phathom Pharmaceuticals, Inc. (1) · Yooyoung Pharmaceutical Co., Ltd. (1)
South Korea (8) · Japan (4) · United States (4) · China (3) · Malaysia (2) · Taiwan (2) · Argentina (1) · Australia (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Greece (1) · Hungary (1) · Italy (1) · Lithuania (1)
Hyun Chae Jung, Ph.D (1) · Kim JinHo (1) · Leah Hollins (1) · Poong Ryul Lee, Ph.D (1) · Sang Woo Lee (1)
PMID 31409606, PMID 36228734, PMID 38654422, PMID 38976448
2019 (1), 2023 (1)